Cipla scheduled results. Cipla stock sits 18.31 percent below target

Published on 10/09/2026 at 12:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cipla stock was at INR 1,307.00 on October 9, 2026 versus INR 1,306.80. JPMorgan set an INR 1,600 target on October 7, 2026.

Key points in brief

Cipla scheduled its next results review for October 27, 2026, covering the quarter and half year ended September 30.
JPMorgan rated Cipla Overweight and set an INR 1,600 target on October 7, 2026.
Cipla stock was at INR 1,307.00 on October 9, 2026, plus 0.02 percent versus INR 1,306.80.

Cipla, INE059A01026, Illustration mit AI erstellt.

Cipla (ISIN INE059A01026) was at INR 1,307.00 on the NSE on October 9, 2026, up 0.02 percent from INR 1,306.80. The company had scheduled its next results review for October 27, 2026, while Financial Express reported on October 7, 2026, that JPMorgan rated the stock Overweight and set an INR 1,600 target. Against the NSE price, that target is 18.31 percent higher.

October results set the next test

According to Cipla in its September 28, 2026 filing, the board will consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing also said the trading window would remain closed from October 1 through October 29, 2026.

The upcoming figures matter because the latest reported quarter combined revenue growth with a sharp profit decline. Simply Wall St reported that first-quarter fiscal 2027 revenue reached INR 70.8 billion, up 3.50 percent year over year, while net income fell 39.00 percent to INR 7.89 billion. Earnings per share dropped to INR 9.77 from INR 16.07.

What does October 27 mean for margins?

The June quarter's profit margin was 11.00 percent, compared with 19.00 percent in the first quarter of fiscal 2026, according to Simply Wall St. The margin gap makes operating expenses a central number for the October review, especially as JPMorgan expects India respiratory, cardio-diabetes and pain therapies to support second-quarter growth.

Three dated developments

On July 24, 2026, Simply Wall St recorded first-quarter fiscal 2027 revenue of INR 70.8 billion and net income of INR 7.89 billion. On July 28, 2026, the same source reported Cipla's US approval for generic Advair Diskus across three strengths, linked to a US market valued at USD 908 million. On September 28, 2026, Cipla set October 27, 2026, for the next results review.

Upcoming dates and stock value

The next dated event is the October 27, 2026 board meeting for second-quarter and first-half fiscal 2027 results. The trading window is scheduled to reopen on October 30, 2026, under the September 28 filing.

Cipla's market capitalization was INR 1.1 trillion on October 9, 2026. Its 52-week NSE range was INR 1,165.70 to INR 1,673.00, placing the current price 21.88 percent below the high. The comparison keeps the valuation question visible beside the operational question: whether the next report shows margin stabilization.

Stock remains below the target

Cipla stock was at INR 1,307.00 on the NSE on October 9, 2026, at 3:15 p.m. IST, versus the prior close of INR 1,306.80. JPMorgan's INR 1,600 target, reported on October 7, 2026, stands 18.31 percent above that price.